RVMD Q2 2023 Earnings — Revolution Medicines, Inc. Revenue & Financial Results | Market Cap Arena

RVMDRevolution Medicines, Inc.

$20B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M-58.1% YoY

Gross Profit

$4M100.0% margin

Operating Income

-$109M-2845.1% margin

Net Income

-$98M-2570.6% margin

EPS (Diluted)

$-0.92

QoQ Revenue Growth

-45.5%

Cash Flow

Operating Cash Flow

-$67M

Free Cash Flow

-$68M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$143M

Stockholders' Equity

$931M

Cash & Equivalents

$380M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$9M	-58.1%
Gross Profit	$4M	$9M	-58.1%
Operating Income	-$109M	-$62M	-75.2%
Net Income	-$98M	-$61M	-60.6%